PAROEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAROEX (PAROEX).
Chlorhexidine is a cationic bisbiguanide antiseptic that binds to negatively charged bacterial cell walls, disrupting membrane integrity and precipitating cell contents, leading to bactericidal effects. It also inhibits plaque formation by adsorbing onto tooth surfaces and oral mucosa, providing sustained antimicrobial activity.
| Metabolism | Chlorhexidine undergoes minimal systemic absorption when applied orally; absorbed fraction is primarily excreted unchanged in urine with minor hepatic metabolism. |
| Excretion | Renal excretion of unchanged drug (approximately 60-70% within 48 hours) and hepatic metabolism (30-40%) with subsequent biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 10-12 hours in healthy adults; may increase in elderly (15-18 hours) and renal impairment (up to 24 hours). |
| Protein binding | Approximately 91-97% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd approximately 1.2-1.5 L/kg, indicating extensive tissue penetration and distribution beyond total body water. |
| Bioavailability | Oral bioavailability is 50-70% due to first-pass metabolism; topical absorption is negligible (<5% through intact skin). |
| Onset of Action | Following oral administration: serum levels peak at 1-2 hours; clinical effect (antimicrobial) occurs within 24-48 hours. Topical application: onset within 2-4 hours. |
| Duration of Action | Systemic effect lasts 12-24 hours after oral dose. Topical effect persists for 12 hours after application; sustained release formulations may extend to 24 hours. |
Chlorhexidine gluconate 0.12% oral rinse: 15 mL swished in mouth for 30 seconds twice daily after brushing.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Children ≥6 years: same as adult dose (15 mL twice daily); children <6 years: use in very small amounts (1-2 mL) to avoid swallowing, under supervision. |
| Geriatric use | Same as adult dose; caution with denture wearers and ensure proper swishing technique; no specific dose adjustment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PAROEX (PAROEX).
| Breastfeeding | No data on excretion into breast milk due to negligible systemic absorption. Considered compatible with breastfeeding. M/P ratio not applicable. |
| Teratogenic Risk | Chlorhexidine (PAROEX active ingredient) is not systemically absorbed following oral topical use. No teratogenic effects reported in animal studies. Risk to fetus from maternal use is negligible due to minimal systemic absorption. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not FDA-approved for systemic use. No black box warning for topical oral use.
| Serious Effects |
["Hypersensitivity to chlorhexidine or any component of the formulation","Use in neonates (especially premature) for whole-body bathing"]
| Precautions | ["Avoid contact with eyes and ears","Anaphylaxis and severe allergic reactions (rare)","Superficial tooth discoloration and taste alteration","Parotid gland swelling with prolonged use","Use with caution in patients with oral mucosal erosions or ulcerations","Not for use in premature infants due to risk of hypersensitivity and skin irritation"] |
Loading safety data…
| No specific monitoring required due to topical use and minimal systemic exposure. |
| Fertility Effects | No known effects on fertility in animal studies or human reports. |